Background: Preeclampsia is a rapidly progressing pregnancy-specific multi-systemic syndrome that is the leading cause of maternal and neonatal morbidity and mortality. Lactate dehydrogenase (LDH) is a valuable and potential biomarker for predicting the severity of Preeclampsia.
Objectives: To assess the level of LDH in women with preeclampsia and to correlate its level with the severity of the disease and maternal/perinatal outcomes.
Patients And Methods: This prospective case-control study was conducted at Sulaimani Maternity Teaching Hospital, Sulaimaniyah, Iraq, from March 1st, 2021, to June 30th, 2022, on 150 pregnant women in 3rd trimester of their pregnancy. Patients (n = 100) were diagnosed with mild and severe Preeclampsia. Serum LDH level was measured and correlated with the severity of the disease and maternal/perinatal outcomes.
Results: LDH was significantly (p = 0.001) elevated in preeclampsia groups compared to the control group. The mild preeclampsia group had a mean LDH level of 302.9 ± 138.5 IU/L, while the severe preeclampsia group had a mean level of 488.6 ± 223.4 IU/L. Also, maternal complications, stillbirth rate, and neonatal intensive Care Unit (NICU) admission were higher in women with high LDH levels.
Conclusions: The serum LDH level is high in women with preeclampsia and correlated with the disease severity as well as maternal and perinatal outcomes. So, serum LDH may be a valuable biomarker for predicting the severity of preeclampsia.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1186/s12905-025-03622-5 | DOI Listing |
BMC Womens Health
March 2025
Sulaimani Maternity Teaching Hospital, Sulaimani Directorate of Health, Sulaimaniyah, Iraq.
Background: Preeclampsia is a rapidly progressing pregnancy-specific multi-systemic syndrome that is the leading cause of maternal and neonatal morbidity and mortality. Lactate dehydrogenase (LDH) is a valuable and potential biomarker for predicting the severity of Preeclampsia.
Objectives: To assess the level of LDH in women with preeclampsia and to correlate its level with the severity of the disease and maternal/perinatal outcomes.
J Ginseng Res
March 2025
Laboratory of Cancer Precision Medicine, The First Hospital of Jilin University, East Minzhu Road, Changchun, Jilin, China.
Aim: Ginsenosides have notable bioactivity in treating cardiovascular diseases, but the mechanisms of their combined use with Peroxiredoxin 6 (PRDX6) in myocardial injury remain unclear. This study explores the synergistic effects of Ginsenoside Rb1 (Gs-Rb1) and PRDX6, aiming to provide a theoretical foundation for their therapeutic potential.
Methods: We established a rat model of isoproterenol (ISO)-induced myocardial injury and observed that combination therapy was more effective than single-drug treatments, as shown by ECG monitoring and Masson staining.
J Nutr Biochem
March 2025
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Anhui Medical University, No.81, Plum Hill Road, Hefei 230032, China; The Comprehensive Experimental Center, School of Basic Medical Sciences, Anhui Medical University, No.81, Plum Hill Road, Hefei 230032, China. Electronic address:
Resveratrol (RSV) ameliorates endothelial dysfunction (ED) primarily through sirtuin 1 (SIRT1). Increasing evidence shows pyroptosis as a novel mechanism in palmitic acid (PA)-induced ED. p66Shc is an adaptor protein involved in oxidative stress.
View Article and Find Full Text PDFAnn Nucl Med
March 2025
Department of Nuclear Medicine, Apollo Hospitals, Greams Lane, 21, Greams Road, Thousand Lights, Chennai, Tamil Nadu, 600006, India.
Objective: This study evaluates the role of Ga-68 Pentixafor PET/CT in staging and follow-up of multiple myeloma (MM) and its correlation with clinical parameters.
Methods: Thirteen participants (9 males, 4 females; median age: 65 years) with MM were recruited in this prospective observational study. Six participants were included for staging evaluation, seven were included for follow-up evaluation, and underwent Ga-68 Pentixafor PET/CT.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!